Successful Intrathecal Rituximab Administration in Refractory Nonteratoma Anti–N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report-Reference-Cited by-同舟云学术

Successful Intrathecal Rituximab Administration in Refractory Nonteratoma Anti–N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report

Published:2019-06-07 Issue:4 Volume:51 Page:194-197
ISSN:1945-2810
Container-title:Journal of Neuroscience Nursing
language:en
Short-container-title:

Author:

Casares Maritsa,Skinner Holly J.,Gireesh Elakkat D.,Wombles Christina,Schweitzer Josephine,Gwyn P. Gage,Newton Herbert B.,Makar Sherif M.,Lee Kihyeong,Westerveld Michael

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Medical–Surgical Nursing,Neurology (clinical),Endocrine and Autonomic Systems,Surgery

Reference8 articles.

1. Anti-NMDA-R encephalitis: follow-up of 24 months;Dement Neuropsychol,2013

2. Treatment and prognostic factors for long-term outcome in patients with anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: a cohort study;Lancet Neurol,2013

3. Rituximab for treatment of refractory anti-NMDA receptor encephalitis in a pediatric patient;J Pediatr Pharmacol Ther,2017

4. Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment;BJPsych Bull,2015

5. Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities;Clin Cancer Res,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphocytes in autoimmune encephalitis: Pathogenesis and therapeutic target;Neurobiology of Disease;2024-10

2. Case report: Rapid recovery after intrathecal rituximab administration in refractory anti-NMDA receptor encephalitis: report of two cases;Frontiers in Immunology;2024-03-06

3. Never Too Late to Treat NMDAR Encephalitis: A Paediatric Case Report and Review of Literature;EMJ Neurology;2022-08-09

4. Autoimmune Encephalitis: Distinguishing Features and Specific Therapies;Critical Care Clinics;2022-04

5. Antibody Therapies in Autoimmune Encephalitis;Neurotherapeutics;2022-01-20